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introduction: Myoclonus–dystonia (M–D) is a young onset movement disorder typically 
involving myoclonus and dystonia of the upper body. A proportion of the cases are 
caused by mutations to the autosomal dominantly inherited, maternally imprinted, epsi-
lon-sarcoglycan gene (SGCE). Despite several sets of diagnostic criteria, identification of 
patients most likely to have an SGCE mutation remains difficult.
Methods: Forty consecutive patients meeting pre-existing diagnostic clinical criteria for 
M–D underwent a standardized clinical examination (20 SGCE mutation positive and 20 
negative). Each video was reviewed and systematically scored by two assessors blinded 
to mutation status. In addition, the presence and coexistence of myoclonus and dystonia 
was recorded in four body regions (neck, arms, legs, and trunk) at rest and with action.
results: Thirty-nine patients were included in the study (one case was excluded owing 
to insufficient video footage). Based on previously proposed diagnostic criteria, patients 
were subdivided into 24 “definite,” 5 “probable,” and 10 “possible” M–D. Motor symptom 
severity was higher in the SGCE mutation-negative group. Myoclonus and dystonia were 
most commonly observed in the neck and upper limbs of both groups. Truncal dysto-
nia with action was significantly seen more in the mutation-negative group (p < 0.05). 
Coexistence of myoclonus and dystonia in the same body part with action was more 
commonly seen in the mutation-negative cohort (p < 0.05).
conclusion: Truncal action dystonia and coexistence of myoclonus and dystonia in the 
same body part with action might suggest the presence of an alternative mutation in 
patients with M–D.
Keywords: myoclonus–dystonia, myoclonus, dystonia, SGCE mutations, motor characteristics
inTrODUcTiOn
Myoclonus–dystonia (M–D) is a rare movement disorder, characteristically with onset in the first 
two decades of life (1). Motor features are typically of myoclonic jerks, predominantly involving the 
upper body, although also involving the lower limbs, face, and larynx in up to a quarter of cases 
(2–4). The dystonic component most frequently involves the neck and upper limbs (writer’s cramp) 
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(5, 6). Both the myoclonus and dystonia may be exacerbated by 
posture, action, or stress. Presentation and progression of motor 
symptoms may vary, ranging from an early childhood-onset 
form starting with upper body or lower limb involvement and 
progressing to upper limbs involvement to a later-onset form, 
with predominant upper body symptoms and frequent cervical 
involvement. The clinical course can be stable or show a progres-
sive course, with increasing severity and/or spreading of symp-
toms (7). Alcohol consumption is widely reported to improve 
motor symptoms, particularly the myoclonus, resulting in excess 
alcohol consumption in some cases (8, 9). Several studies have 
also identified psychiatric symptoms in M–D cohorts, includ-
ing anxiety, panic attacks, and obsessive–compulsive disorder 
(10–12).
Myoclonus–dystonia is inherited in an autosomal dominant 
fashion with mutations in the maternally imprinted SGCE 
gene (DYT11) observed in a proportion of cases (13–15). 
At present, clinical discrimination of SGCE mutation-positive 
from mutation-negative M–D cases remains difficult. Previous 
studies have shown the frequency of SGCE mutations in M–D 
cohorts to vary between 21 and 85% dependent on the inclu-
sion criteria employed (3, 4, 6, 16–19). Several factors have 
been proposed as predictors of an SGCE mutation, including 
motor symptom onset <20 years, a positive family history of a 
similar movement disorder, and comorbid psychiatric symptoms 
(19–21).
A classification system has been developed to determine 
the likelihood of an SGCE mutation in individual cases, with 
subgroups “definite,” “probable,” or “possible,” based on the 
distribution of motor symptoms, age at onset, and presence or 
absence of a family history (Table S1 in Supplementary Material) 
(18). Refinement of these diagnostic criteria has been proposed to 
include a positive family history with specific paternal transmis-
sion and normal brain imaging (5), or the combination of young 
onset motor symptoms with psychiatric features (20). However, 
it remains difficult to identify those patients most likely to have 
an SGCE mutation.
The aim of this study is to determine whether the character-
istics of motor signs observed during clinical examination can 
be of help in identifying carriers of a SGCE mutation. Particular 
emphasis was placed on whether coexistence of myoclonus and 
dystonia in the same body part was helpful in distinguishing 
those with and without an SGCE mutation. We hypothesized that 
SGCE mutation-negative patients with “jerky dystonia” would 
more often present with jerky movements superimposed on the 
dystonic posture in the same body part, whereas for those with 
an SGCE mutation the myoclonus and dystonia would be evident 
independently and in different body regions.
MaTerials anD MeThODs
Following informed consent, 40 consecutive M–D patients from 
the movement disorders service at the Academic Medical Center, 
Amsterdam, The Netherlands were recruited for the study (20 
SGCE positive and 20 SGCE negative). Participants were divided 
into one of the three diagnostic categories, “definite,” “probable,” 
and “possible,” according to previously proposed diagnostic 
criteria (Table S1 in Supplementary Material). All participants 
underwent a videotaped clinical examination, which in the 
majority of cases followed a standardized protocol (n = 31), and 
the remaining cases were examined as part of routine clinical 
practice (n = 9). Each videotaped examination was subsequently 
assessed by two of the three independent movement disorder 
experts (Maria Fiorella Contarino, Hans Speelman, and Joke M. 
Dijk), blinded to the genetic status of the participant.
The motor section of the Burke–Fahn–Marsden Dystonia 
Rating Scale (BFMDRS) and sections 2 (myoclonus at rest) and 
4 (action myoclonus) of the Unified Myoclonus Rating Scale 
(UMRS) were used to assess motor symptom severity (22). In 
addition, the presence and coexistence of myoclonus and dys-
tonia were recorded in four body regions (neck, arms, legs, and 
trunk), at rest and with action. In the absence of adequate video 
footage to allow evaluation of a specific body region in individual 
patients, the score for this region was omitted.
The Ethical Board of the Academic Medical Center of 
Amsterdam approved the study.
statistical analysis
Clinical features were analyzed using the Fisher’s exact test or 
Student’s t-test where appropriate. Inter-rater reliability was 
assessed using intraclass correlation coefficients (ICCs) (two 
way mixed, consistency, and average measures). ICC results 
were further classified as; 0.91–1: excellent, 0.71 and 0.9: good, 
0.51 and 0.70: moderate, <0.5: poor, and <0.3: very poor (23). 
The inter-rater reliability of the new evaluation tool was reported 
both in absolute agreement and percentage of agreement 
between raters.
resUlTs
Demographic characteristics
A full summary of the demographic characteristics of this cohort 
is reported in Table 1. Due to the consecutive nature of recruit-
ment, mutation-positive and -negative groups were not matched 
for gender and age at the onset of motor symptoms. The SGCE 
mutation-positive cohort included a greater number of cases with 
motor symptom onset <20 years and a positive family history. 
There were no significant differences in demographic character-
istics between the groups.
Overall, 39 patients (25F: 14M) with a clinical M–D phenotype 
were included in the study. Nineteen had an SGCE mutation (one 
mutation-positive case was excluded owing to insufficient video 
footage) and 20 patients were mutation negative. Median age at 
examination was 39  years (range: 14–75). Myoclonus was the 
presenting feature in 28 cases, dystonia in 8 and both myoclonus 
and dystonia were observed at symptom onset in 3. Details of 
the cognitive and psychological characteristics of this cohort have 
been published elsewhere (12).
The SGCE mutation-positive cohort (n  =  19, 10F: 9M) 
included 13 probands and had a median age at examination of 
41 years (range: 15–75). Seventeen cases had onset of symptoms 
<20 years of age with single cases developing motor symptoms 
TaBle 1 | Demographic characteristics.
SGCE mutation positive
Proband only cohort  
(n = 13)
SGCE mutation positive 
all patients  
(n = 19)
SGCE mutation  
negative cohort (n = 20)
SGCE positive vs.  
SGCE negative  
(p-value)
Gender
 Male/female 5/8 9/10 5/15 0.19
Age median (range) 40 (15–60) 41 (15–75) 36 (14–61) 0.56
Age at onset
 ≤20 years/>20 years 12/1 17/2 12/8 0.07
Symptom at onset
 Myoclonus 9 13 15 0.73
 Dystonia 1 3 5 0.70
 Myoclonus and dystonia 3 3 0 0.11
Alcohol responsiveness
 Responsive 5 5 6 0.23
 Unresponsive 0 0 4
 Unknown 8 14 10
Family history
 Positive/negative 13/0 … 8/12 0.00
“Grunewald classification”
 “Definite” 12 17 7 0.00
 “Probable” 0 1 4 0.34
 “Possible” 1 1 9 0.01
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in each of the 30- to 40-year and 40- to 50-year age brackets. 
Applying Grunewald diagnostic criteria, this group was further 
subdivided into 17 “definite,” 1 “probable,” and 1 “possible” cases.
The SGCE mutation-negative cohort (n = 20, 15F: 5M) had 
a median age at examination of 36 years (range: 14–61). Motor 
symptom onset was <20 years in 12 cases, 30–40 years in 4 cases, 
40–50 years in 3 cases, and >50 years in a single participant. With 
application of the same diagnostic criteria, this group was sub-
divided into 7 “definite,” 4 “probable,” and 9 “possible.”
Due to a sub-optimal video footage, 11/76 (at rest) and 11/76 
(with action) dystonia and 2/76 (at rest) and 3/76 (with action) 
myoclonus video assessment sections were scored as missing in 
the SGCE mutation-positive cohort. In the mutation-negative 
group, 2/80 (at rest) and 3/80 (with action) dystonia while none 
of the myoclonus assessment sections incomplete.
Distribution of symptoms
Myoclonus and dystonia were most commonly observed in the 
neck and arms in both mutation positive and negative groups. 
Comparison of the SGCE mutation-positive probands and the 
mutation-negative group identified significant difference with 
truncal dystonia during action [8/19 (SGCE mutation-negative) 
0/13 (SGCE mutation-positive probands only); p  =  0.01, OR 
0.01, 95% CI (0.00, 0.74)]. This difference was preserved when 
extended to include the entire mutation-positive group: truncal 
dystonia [8/19 (SGCE mutation-negative) 1/17 (SGCE mutation-
positive); p = 0.02, OR 0.09, 95% CI (0.00, 0.88)] (Tables 2 and 3; 
Figure S1 in Supplementary Material).
coexistence of Myoclonus and Dystonia
At rest, there was no significant difference between the proband-
only mutation-positive group and those without an SGCE 
mutation in the coexistence of myoclonus and dystonia in the 
same body part, either overall or by individual body part. Overall 
assessment with action showed a significant difference between 
the two groups [p = 0.01, OR = 0.11, 95% CI (0.01, 0.73)], being 
the coexistence more common in the mutation-negative group, 
although no difference was observed between individual body 
parts. Inclusion of the entire mutation-positive cohort showed 
similar results overall [p = 0.01, OR 0.13, 95% CI (0.02, 0.71)] and 
a trend toward significance when examining the cervical region 
[p = 0.09, OR = 0.26, 95% CI (0.05, 1.26)]. A full summary of the 
rates and distribution of coexistent myoclonus and dystonia can 
be seen in Table 4.
severity of Myoclonus and Dystonia with 
Use of BFMDrs and UMrs rating scales
The median total BFMDRS score was significantly higher in the 
SGCE mutation negative group [6/120 (range: 4–47)] vs. 3.5/120 
(range: 0–11) than in the mutation-positive group (p <  0.05). 
A higher median UMRS total score was also observed in the 
SGCE-negative patients [25/240 (range: 0–92)] compared to 
14.5/240 (range: 0–80) in the mutation-positive group (p > 0.05), 
although this difference was not statistically significant.
inter-rater agreement
Two assessors evaluated the SGCE mutation-negative group 
using both BFMDRS and UMRS rating scales, achieving an 
inter-rater concordance of “good” [ICC BFMDRS =  0.91 (95% 
CI: 0.74–0.97)/ICC UMRS =  0.87 (95% CI: 0.60–0.96)]. Each 
rating scale was scored by a single assessor during evaluation 
of the mutation-positive patients (Table S2 in Supplementary 
Material). In evaluating co-occurrence of myoclonus and dysto-
nia, overall agreement between the two assessors was 88% at rest 
TaBle 4 | comparison of co-existent myoclonus and dystonia in the same body region in SGCE mutation-positive and -negative cohorts.
Myoclonus and 
dystonia
SGCE positive
all  
(n = 19)
SGCE positive
Proband only  
(n = 13)
SGCE negative 
(n = 20)
statistical comparison
all/negative p-value  
(Or; 95% ci)
statistical comparison
Proband only/negative  
p-value (Or; 95% ci)
Rest
Overall 10 8 15 0.19 (0.37; 0.08, 1.73) 0.46 (0.53; 0.09, 3.05)
Neck 10 8 13 0.74 (0.67; 0.15, 3.01) 1.00 (0.86; 0.16, 4.63)
Upper limbs  0 0  2 NA NA
Trunk  0 0  0 NA NA
Lower limbs  1 1  1 1.00 (1.50; 0.04, 62.14) 1.00 (1.80; 0.04, 75.80)
Action
Overall  8 5 17 0.01 (0.13; 0.02, 0.71) 0.01 (0.11; 0.01, 0.73)
Neck  6 5 14 0.09 (0.26; 0.05, 1.26) 0.15 (0.31; 0.05, 1.71)
Upper limbs  5 4  8 0.51 (0.58; 0.12, 2.74) 0.72 (0.67; 0.12, 3.65)
Trunk  1 0  4 0.34 (0.23; 0.01, 2.75) 0.13 (0.00; 0.00, 2.21)
Lower limbs  0 0  0 NA NA
Key: statistically significant differences (p < 0.05) between SGCE mutation-positive and -negative groups are highlighted in bold.
NA, not applicable.
Fisher’s exact test was used for statistical comparison.
TaBle 3 | Distribution of dystonia at rest and with action.
Dystonia SGCE positive
all  
(n = 19)
SGCE positive 
Proband only  
(n = 13)
SGCE negative 
(n = 20)
statistical comparison
all/negative p-value  
(Or; 95% ci)
statistical comparison
Proband only/negative  
p-value (Or; 95% ci)
Rest
Neck 14 11 19 0.17 (0.18; 0.01, 2.14) 0.55 (0.29; 0.01, 4.90)
Upper limbs  2  2  2 1.00 (1.20; 0.10, 14.07) 1.00 (1.64; 0.14, 19.91)
Trunk  0  0  4 NA NA
Lower limbs  1  1  2 1.00 (0.71; 0.02, 12.05) 1.00 (0.85; 0.03, 14.84)
Action
Neck  7  5 16 0.04 (0.19; 0.03, 1.04) 0.05 (0.18; 0.03, 1.10)
Upper limbs  6  5 11 0.21 (0.41; 0.09, 1.84) 0.48 (0.51; 0.10, 2.63)
Trunk  1  0  8 0.02 (0.09; 0.00, 0.88) 0.01 (0.00; 0.00, 0.74)
Lower limbs  3  3  6 1.00 (0.73; 0.11, 4.43) 0.69 (0.55; 0.08, 3.44)
Key: statistically significant differences (p < 0.05) between SGCE mutation-positive and -negative groups are highlighted in bold.
NA, not applicable.
Fisher’s exact test was used for statistical comparison.
TaBle 2 | Distribution of myoclonus at rest and with action.
Myoclonus SGCE positive
all  
(n = 19)
SGCE positive
Proband only  
(n = 13)
SGCE negative 
(n = 20)
statistical comparison 
all/negative, p-value  
(Or; 95% ci)
statistical comparison
Proband only/negative,  
p-value (Or; 95% ci)
Rest
Neck 12 9 13 1.00 (0.92; 0.21, 4.15) 1.00 (1.21; 0.22, 6.97)
Upper limbs  5 4 13 0.05 (0.22; 0.04, 1.09) 0.08 (0.24; 0.04, 1.32)
Trunk  7 5  3 0.07 (4.41; 0.74, 29.07) 0.12 (4.05; 0.59, 30.64)
Lower limbs  3 2  6 1.00 (0.70; 0.10, 4.41) 0.68 (0.52; 0.06, 4.00)
Action
Neck 10 8 16 0.29 (0.42; 0.07, 2.30) 0.43 (0.50; 0.07, 3.30)
Upper limbs 12 9 14 1.00 (0.86; 0.18, 4.14) 1.00 (0.96; 0.17, 5.68)
Trunk  6 4  6 1.00 (1.27; 0.26, 6.29) 1.00 (1.04; 0.18, 6.02)
Lower limbs  3 2  3 0.67 (1.55; 0.20, 12.33) 1.00 (1.13; 0.11, 10.83)
Fisher’s exact test was used for statistical comparison.
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and 84% with action. Evaluation of individual body parts showed 
the strongest concordance when assessing the truncal region 
(94%, 34/36) and the lowest rate of agreement when evaluating 
movements of the neck with action (64%, 23/36). A summary of 
the positive agreement between assessors can be seen in Table S3 
in Supplementary Material.
DiscUssiOn
This study examined the distribution and coexistence of myo-
clonus and dystonia, at rest and with action, as a predictive factor 
in determining the presence of an SGCE mutation in patients with 
an M–D phenotype. We have demonstrated that truncal dystonia 
and coexistence of myoclonus and dystonia in the same body 
region with action are more frequently observed in those without 
an SGCE mutation.
Application of the Grunewald diagnostic criteria to this study 
cohort did not clearly distinguish between those with and without 
an SGCE mutation. Seven on those without a mutation were 
deemed to be in the “definite” diagnostic category, while a two 
individuals with mutations were placed, one each, in the “prob-
able” and “possible” groups. In keeping with the current diagnostic 
criteria, myoclonus and dystonia were most frequently observed 
in the neck and arms of both mutation positive and negative 
cohorts, with onset of symptoms <20 years being more frequent 
in those with an SGCE mutation (17/19 vs. 12/20) (5, 18). A posi-
tive family history was more frequently observed among those 
with an SGCE mutation and therefore increased the number of 
cases in the “definite” diagnostic category. The mutation-positive 
cohort consisted of 13 probands with an additional 6 affected 
cases recruited from two families, reflecting an inherent recruit-
ment bias from a specialist tertiary movement disorder service. 
It could also be argued that by recruiting multiple members of 
the same kindred, additional genetic and environmental factors 
may also be contributing to their motor phenotype. However, 
little difference in results was observed when comparing both 
the proband only and complete SGCE mutation-positive cohort 
to the mutation-negative group, suggesting that any potential 
additional factors had little effect in the outcome of this study. In 
addition, multiple case reports and case series have demonstrated 
significant intra-familial motor variability among those with 
SGCE mutations (4).
It is worth mentioning that mutations in other genes, includ-
ing KCTD17, THD, and RELN, have been recently associated 
with M–D, although confirmation in a larger number of families 
is still needed (24–26). Available data suggest that the phenotype 
associated with these mutations might slightly differ from that 
associated with SGCE mutation. For example the KCTD17 gene 
mutation is characterized by a milder myoclonus affecting the 
upper limbs and progressive dystonia spreading from the crani-
ocervical region to other sites. The patients in our cohort were not 
screened for these mutations, which could potentially account for 
some of the SCGE-negative cases.
Although multiple previous reports have commented on wors-
ening of motor features with action in M–D cohorts, none of the 
previous studies have directly compared the nature and frequency 
of the movement disorder between an SGCE mutation-positive 
cohort and a suitable mutation-negative control group, both 
at rest and with action. Overall, no difference between the two 
groups was observed at rest; however, coexistence of myoclonus 
and dystonia in the same body area was significantly more fre-
quent with action in the mutation-negative cohort (p < 0.05) with 
a trend toward significance observed in the cervical region with 
action (p =  0.09). These observations of coexistent myoclonus 
and dystonia in the same body region in those without an SGCE 
mutation may reflect a “jerky” dystonia rather than myoclonus. 
These two forms of hyperkinesias are known to be difficult to dif-
ferentiate, both in clinical practice and assessment of videotaped 
examination. It may be contributory to include neurophysiologi-
cal testing in future studies to aid in differentiating between these 
two forms of movement disorder (27).
Multi-rater comparison of clinical cases can potentially result 
in significant variability of clinical opinion. Overall inter-rater 
agreement between the movement disorder specialists involved 
in this study was good. Disparities in scoring were predominantly 
observed in the cervical region where dystonic “overflow” or 
movement of other body parts can cause diagnostic difficulty. 
These results highlight the notoriously difficult task of hyperki-
netic movement disorder phenomenology, particularly when two 
or more movement disorder subtypes may coexist in the same 
body region. This study can be regarded as a pilot study due to the 
relatively small number of patients in each study group ultimately 
preventing further and more elaborate statistic analysis of the 
available results. Future studies will require large, multicenter 
collaboration in order to enable recruitment of sufficiently large 
and diverse cohorts to allow definitive conclusions to be drawn.
cOnclUsiOn
The results of this pilot study suggest that the presence of 
truncal dystonia and the coexistence of myoclonus and 
dystonia in the same body region with action reduce the 
likelihood of SGCE mutation in patients with an M–D phe-
notype. Larger series are needed to confirm our preliminary 
findings before they can be translated into clinical practice. 
These results highlight the importance of examining move-
ment disorders both at rest and with action during clinical 
assessment, particularly, when selecting those patients to 
undergo specific genetic testing.
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